14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
UNOV vs REGN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Innovator U.S. Equity Ultra Buffer ETF - November (UNOV) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). UNOV carries a Unified Composite Score of 58.7/100 (HOLD) at $41.13 (N/M Forward P/E, N/A operating margin), whereas REGN carries 38.6/100 (SELL) at $952.40 (15.3x Forward P/E, 30.4% operating margin).
Composite vs. Pillar Nuance: While UNOV currently prints a higher short-term Unified Composite Score (58.7/100 HOLD vs. REGN 38.6/100 SELL), REGN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (30.4% vs. N/A operating margin) and revenue trajectory (+36.3% vs. N/A YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UNOV vs REGN. Trailing 12-month operating profitability (UNOV N/A vs REGN 30.4%) and valuation multiples (UNOV N/M vs REGN 15.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Pharmaceutical Preparations value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
REGN Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $98.8B market capitalization and 30.4% operating margin.
OpEx & R&D Reinvestment16.3% of Rev ($2.75B)
90D Engineering Disclosures0 Published
Investor FAQ UNOV vs REGN Key Questions & Quantitative Answers
As of Nov 16, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Innovator U.S. Equity Ultra Buffer ETF - November (UNOV) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). UNOV carries a Unified Composite Score of 58.7/100 (HOLD) at $41.13 (N/M Forward P/E, N/A operating margin), whereas REGN carries 38.6/100 (SELL) at $952.40 (15.3x Forward P/E, 30.4% operating margin). Composite vs. Pillar Nuance: While UNOV currently prints a higher short-term Unified Composite Score (58.7/100 HOLD vs. REGN 38.6/100 SELL), REGN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (30.4% vs. N/A operating margin) and revenue trajectory (+36.3% vs. N/A YoY).
REGN leads the Growth & Scale pillar: UNOV posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with REGN at +36.3% YoY revenue growth and +35.5% YoY earnings growth on $16.9B TTM revenue (46.7% gross margin, 30.4% operating margin). On trailing 12-month operating scale, UNOV generates N/A in USD-normalized revenue versus $16.9B for REGN. In operating R&D and SG&A reinvestment, UNOV deploys N/A (0 90-day corporate R&D disclosures) versus 16.3% of Rev ($2.75B) (0 disclosures) for REGN.
REGN screens cheaper on headline valuation multiples. UNOV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas REGN trades at 15.3x Forward P/E, 21.1x Trailing P/E, 1.16x PEG, and 5.8x EV/Revenue (21.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UNOV (N/A ROE) versus REGN (14.9% ROE) capital efficiency.
In options market volatility and institutional positioning, UNOV carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.46β · 11% Vol realized risk). By comparison, REGN carries 35.9% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.38x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.33β · 55% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.